Sun Pharma Announces Special Window for Physical Share Transfers
Sun Pharma is facilitating a special one-year window (Feb 5, 2026 - Feb 4, 2027) for transferring physical shares sold before April 1, 2019. Transferred shares will be in demat mode and locked in for one year. Advertisements were published on May 20, 2026.
This is a routine regulatory compliance announcement aimed at facilitating share transfers for a specific historical period. It does not directly impact the company's current operations, financials, or strategic direction.
The announcement is a procedural update regarding a SEBI directive to facilitate share transfers and does not contain any new financial or operational information that would impact the company's outlook.
Sun Pharmaceutical Industries Limited has announced the opening of a special window for the transfer of physical shares. This initiative, in line with SEBI's circular dated January 30, 2026, allows for the transfer of physical shares sold or purchased before April 1, 2019. The window will remain open for one year, from February 5, 2026, to February 4, 2027.
During this period, any shares transferred will be credited to the transferee's demat account and will be under a lock-in for one year from the registration date. These shares cannot be transferred, lien-marked, or pledged during the lock-in period. Investors holding physical shares are encouraged to submit the necessary documents to the company's Registrar and Transfer Agent, MUFG Intime India Private Limited, within the specified timeframe.
The company has published advertisements in the Financial Express (English and Gujarati editions) on May 20, 2026, to inform investors about this special window. Further information will also be disseminated through social media platforms like X, LinkedIn, and Facebook.
What to do with a filing like this
Sun Pharmaceutical Industries Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sun Pharmaceutical Industries Limited. Read the original for the full detail.